Developing nasal-spray, self-adjuvanting vaccines for viral respiratory diseases based on our Delta NS1 technology platform: DeltaFLU: Universal Influenza Vaccine in Phase 2 clinical development for broad protection against all strains of influenza. Delta-19: Covid-19 + Universal Influenza combination vaccine to address the double pandemic threat of SARS-CoV-2 and influenza.
